ClinicalTrials.gg
CompletedNCT00610077Updated Feb 7, 2008

Letrozole vs. Clomiphene Citrate in Patients With Anovulatory Infertility

A Phase 3 interventional study of Letrozole and Clomiphene citrate in Infertility, sponsored by Sun Pharmaceutical Industries Limited. Completed at 1 site in India. Open to female participants aged 20 Years to 38 Years. Per ClinicalTrials.gov, last updated 2008-02-07.

Sponsored by Sun Pharmaceutical Industries Limited · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
20 Years to 38 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 31 studies testing letrozole in Infertility — 2 open to participants now, 3 under way, 2 of them phase 3. Letrozole · Infertility.

Enrollment
23rd of 31
55 · median 131
Started
2004
the only one that year
Phase 3
10 of 31
1 open now
Registered
2nd of 31
by date

Among the 31 studies testing letrozole in Infertility, this one is the 23rd largest by enrollment, is the only one that started in 2004, is one of 10 in phase 3, and was the 2nd registered.

Infertility

2,089 studies on the registry are indexed under Infertility; 356 are open to participants now.

Browse Infertility studies →

Open to participants now

2 of the 31 studies testing letrozole in Infertility are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About letrozole

Letrozole: first FDA approval 1997 (FEMARA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 234 Infertility studies recruiting now, 43 (18%) set no upper age limit and 185 (79%) stop at 75 or younger; 27 take children under 18; 76 take healthy volunteers.

This study: 20 Years to 38 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing letrozole in Infertility, or all of them as a file.
02

Study summary

OBJECTIVE: To compare the effectiveness of letrozole and clomiphene citrate (CC) in patients with anovulatory infertility. DESIGN: Open, prospective, randomized, parallel group, multicentric, comparative trial. SETTING: Out patient clinics of infertility centers in India. PATIENT(S): Fifty-five patients with anovulatory infertility were recruited. Twenty-seven patients (59 cycles) were given letrozole and twenty-eight patients (68 cycles) were given CC. Both drugs were given orally on days 3-7 of menstrual cycle. INTERVENTION(S): Letrozole, CC, ovulation induction, vaginal micronized progesterone, IUI.

Read the detailed description

MAIN OUTCOME MEASURE(S): Occurrence of ovulation, endometrial thickness and pregnancy rates.

03

Conditions studied

  • Infertility

Browse trials for

Keywords

  • Letrozole
  • Clomiphene citrate
  • Anovulatory infertility
  • Ovulation induction
04

Who can participate

Ages eligible
20 Years to 38 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females with anovulatory infertility 20-38 years of age.
  • Diagnosis of anovulatory infertility as established by standard criteria.
  • Normal Pelvic USG and bilateral tubal patency
  • Willingness and giving written .

Exclusion criteria

Exclusion Criteria:

  • Uterine and adnexal pathology e.g. leiomyomata
  • Ovarian cyst
  • Hyperprolactinaemia
  • Hyperthyroidism or Hypothyroidism*
  • FSH >9mIU/ml (during early follicular phase).* (As per Chemoluminescence method)
  • Previous surgery related to genital tract as per history
  • Appendicitis, peritonitis, genital tuberculosis as per history and/or having an abnormal pelvic anatomy
  • Impaired hepatic /renal function
  • Diabetes mellitus/Random blood sugar- > 140mg/dl
  • Drugs likely to interfere with ovulation
  • Alcohol intake as per history
  • History of to the study drug or to its
  • Planned travel outside the study area for a substantial portion (>5 days) of the study period by potential participants
  • Lack of willingness to give informed written consent
  • Participation in any clinical study within the preceding 1 month
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    1

    Letrozole

    Drug: Letrozole

  • Active comparator
    2

    Clomiphene citrate

    Drug: Clomiphene citrate

Interventions

  • Tablet Letrozole 2.5 mg once a day for 5 days for 3 cycles

    Also known as: Letroz

  • Clomiphene citrate 100 mg or 150 mg once a day for 5 days in 3 cycles

    Also known as: Ferotab

06

What researchers measure

Primary outcomes

  1. Ovulation rate (ovulatory cycles/ all treatment cycles) by Ultrasonography (USG).

    Time frame: 3 cycles

Secondary outcomes

  1. Pregnancy Rate (Detection of pregnancy by beta-hCG and Ultrasonography) b. Endometrial thickness by Ultrasonography.

    Time frame: 3 cycles

  2. Safety

    Time frame: 3 cycles

07

Study locations

1 site
  • IVF Centre, Chembur,
    Mumbai-, Maharashtra 400071, India
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2004, a primary completion of Jul 2006 and a completion of Jul 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2008
First posted
Feb 7, 2008
Start
Dec 2004
Primary completionActual
Jul 2006
CompletionActual
Jul 2006
Last update
Feb 7, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00610077
First posted
Feb 7, 2008
Start date
Dec 2004
Primary completion
Jul 2006
Completion
Jul 2006
Last update
Feb 7, 2008

Study contacts

Mandakini Parihar, M.D., D.G.O.
principal investigator · Director, IVF Centre, Chembur

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letrozole

Start the discussion